Milestone Pharmaceuticals (NASDAQ:MIST) Announces Quarterly Earnings Results

Milestone Pharmaceuticals (NASDAQ:MIST) issued its quarterly earnings results on Friday. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04, FiscalAI reports. The company had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $1.00 million.

Here are the key takeaways from Milestone Pharmaceuticals’ conference call:

• CARDAMYST prescriptions rose 50% quarter over quarter to approximately 1,800, while unique prescribers increased to about 750. Commercial formulary coverage reached roughly two-thirds of covered lives, and third-quarter net product revenue grew to $1.0 million from $0.6 million in Q2.
• Milestone expects its cost-efficiency measures—including bringing its 45-person sales team in-house and focusing spending on higher-impact activities—to reduce operating expenses by about 30%. The company expects to complete the changes by Q1 2027, with approximately $2 million in one-time charges.
• Milestone said the cost reductions and an extension of its payment-in-kind interest period are expected to extend its cash runway into late 2028, through the anticipated ReVeRA-301 Phase III readout in the second half of 2028. The trial is enrolling patients in the U.S., Canada, and Europe.
• Third-quarter selling, general, and administrative expense rose to $24.2 million from $7.9 million a year earlier, primarily due to CARDAMYST launch costs; net loss widened to $25.8 million from $11.9 million. Management also noted that prescription growth remains gradual and expects possible seasonal pressure in Q1 as insurance out-of-pocket costs reset.
• Management views emergency-department and ambulance use as potential longer-term opportunities, but said operational hurdles make them a lower priority over the next 12–18 months. Medicare is also not expected to drive near-term prescription growth, with the company favoring selective coverage over broad Part D discounts.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST traded down $0.14 during midday trading on Friday, reaching $0.52. 3,923,794 shares of the company were exchanged, compared to its average volume of 1,748,552. The stock has a market cap of $64.74 million, a PE ratio of -0.75 and a beta of 1.07. The business’s fifty day moving average is $0.82 and its two-hundred day moving average is $1.32. Milestone Pharmaceuticals has a one year low of $0.50 and a one year high of $3.06. The company has a current ratio of 8.13, a quick ratio of 7.92 and a debt-to-equity ratio of 3.25.

Trending Headlines about Milestone Pharmaceuticals

Here are a few of the latest headlines about MIST:

• Positive Sentiment: MIST reported a third-quarter loss of $0.18 per share, narrower than analysts’ expected $0.22 loss, and revenue of $2.96 million versus the $1.00 million consensus estimate. Zacks Q3 results
• Positive Sentiment: The company plans to cut operating expenses by about 30%, while keeping its sales team and AFib-RVR Phase 3 program in place. It expects $145.4 million in cash and investments to fund operations into late 2028, beyond the trial’s anticipated second-half 2028 data readout. Company results and cost-efficiency measures
• Negative Sentiment: The quarterly net loss more than doubled year over year to $25.8 million from $11.9 million. CARDAMYST revenue remains modest, while selling, general and administrative expenses rose sharply with the product launch. Quarterly financial results

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, October 12th. Finally, Cantor Fitzgerald began coverage on shares of Milestone Pharmaceuticals in a report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Milestone Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $6.40.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.